Clinical trials update from the European Society of Cardiology heart failure meeting 2009: CHANCE, B-Convinced, CHAT, CIBIS-ELD, and Signal-HF

European Journal of Heart Failure

Volumn 11, Issue 8, 2009, Pages 802-805

  Cleland, John G F ^a   Coletta, Alison P ^a   Torabi, Azam ^a   Clark, Andrew L ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Heart failure; Randomized controlled trials

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

CLINICAL STUDY; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; HEALTH PROGRAM; HEART FAILURE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MEDICAL SOCIETY; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; RURAL AREA; TREATMENT OUTCOME; AGED; CARDIOLOGY; CLINICAL TRIAL (TOPIC); DISEASE COURSE; EUROPE; FEMALE; MALE; MIDDLE AGED; ORGANIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SIGNAL TRANSDUCTION; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; CARDIOLOGY; CLINICAL TRIALS AS TOPIC; CONGRESSES AS TOPIC; DISEASE PROGRESSION; EUROPE; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SIGNAL TRANSDUCTION; SOCIETIES, MEDICAL;

EID: 67749119913     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfp102     Document Type: Conference Paper

References (20)

1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-989.
2. Metra M, Torp-Pedersen C, Cleland JG, Di Lenarda A, Komajda M, Remme WJ, Dei Cas L, Spark P, Swedberg K, Poole-Wilson PA; COMET Investigators. Should beta-blocker therapy be reduced or withdrawn after an episode of decompen-sated heart failure? Results from COMET. Eur J Heart Fail 2007;9:901- 909.
3. Orso F, Baldasseroni S, Fabbri G, Gonzini L, Lucci D, D'Ambrosi C, Gobbi M, Lecchi G, Randazzo S, Masotti G, Tavazzi L, Maggioni AP, on behalf of Italian Survey on Acute Herat Failure Investigators. Role of beta-blockers in patients admitted for worsening heart failure in a real world setting: data from the Italian Survey on Acute Heart Failure. Eur J Heart Fail 2009;11:77-84.
4. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB; OPTIMIZE-HF Investigators and Coordinators. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol 2008;52:190-199.
5. Clark RA, Yallop JJ, Piterman L, Croucher J, Tonkin A, Stewart S, Krum H; CHAT study team. Adherence, adaptation and acceptance of elderly chronic heart failure patients to receiving healthcare via telephone monitoring. Eur J Heart Fail 2007;9: 1104-1111.
6. Cleland JGF. How to assess new treatments for the management of heart failure: composite scoring systems to assess the patient's clinical journey. Eur J Heart Fail 2002;4:243-247.
7. Dungen HD, Apostolovic S, Inkrot S, Tahirovic E, Krackhardt F, Pavlovic M, Putnikovic B, Lainscak M, Gelbrich G, Edelmann F, Wachter R, Eschenhagen T, Waagstein F, Follath F, Rauchhaus M, Haverkamp W, Osterzeil KJ, Dietz R; CIBIS-ELD Investigators. Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD study. Clin Res Cardiol 2008;97: 578-586.
8. Komajda M, Anker SD, Charlesworth A, Okonko D, Metra M, Di Lenarda A, Remme W, Moullet C, Swedberg K, Cleland JG, Poole-Wilson PA. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J 2006;27:1440-1446.
9. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scerhag A, Skene A; COMET investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial (COMET): randomised controlled trial. Lancet 2003;362:7-13.
10. Hernandez AF, Hammill BG, O'Connor CM, Schulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of beta-blockers in heart failure. Findings from the OPTIMIZE registry. J Am Coll Cardiol 2009;53:184-192.
11. Cleland JGF, Coletta AP, Clark AL, Cullington D. Clinical trials update from the American College of Cardiology 2009: ADMIRE-HF, PRIMA, STICH, REVERSE, IRIS, partial ventricular support, FIX-HF-5, vagal stimulation, REVIVAL-3, pre-RELAX-AHF, ACTIVE-A, HF-ACTION, JUPITER, AURORA, and OMEGA. Eur J Heart Fail 2009;11:622-630.
12. Coletta AP, Cullington D, Clark AL, Cleland JGF. Clinical trials update from European Society of Cardiology Meeting 2008: TIME-CHF, BACH, BEAUTIFUL, GISSI-HF and HOME-HF. Eur J Heart Fail2008;10:1264-1267.
13. Maisel A, Mueller C, Adams K, Anker S, Aspromonte N, Cleland JGF, Cohen-Solal A, Dahlstrom U, DeMaria A, Di Somma S, Filippatos GS, Fonarow GC, Jourdain P, Komajda M, Liu PP, McDonagh T, McDonald K, Mebazza A, Nieminen MS, Peacock WF, Tubaro M, Valle R, Vanderhyden M, Yancy CW, Zannad F, Braunwald E. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail2008;10:824-839.
14. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, Vuillomenet A, Jeker U, Dubach P, Beer H, Yoon SI, Suter T, Osterhues HH, Schieber MM, Hilti P, Schindler R, Brunner-La Rocca HP; TIME-CHF Investigators. BNP-guided vs symptom-guided heart failure therapy: the trial of intensified vs standard medical therapy in elderly patients with congestive heart failure (TIME-CHF) randomized trial. J Am Med Assoc 2009;301:383-392.
15. Lainchbury JG, Troughton RW, Frampton CM, Yandle TG, Hamid A, Nicholls MG, Richards AM. NT-proBNP guided drug treatment for chronic heart failure: design and methods in the BATTLESCARRED trial. Eur J Heart Fail 2006;8:532-538.
16. Cleland JGF, Atkin SL. Thiozolidinediones, deadly sins, surrogates and elephants. Lancet 2007;370:1103-1104.
17. Flather MD, Shibata MC, Coats AJS, van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Bohm M, Anker SD, Thompson SG, Poole-Wilson PA, SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-225.
18. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vitovec J, Aldershvile J, Halinen M, Diez R, Neuhaus KL, Janosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottleib S, Deedwania P. Effects of controlled-release metoprolol on total mortality, hospitalizations and well-being in patients with heart failure: the metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). MERIT-HF study group. J Am Med Assoc 2000;283:1295-1302.
19. Simon T, Mary-Krause M, Funck-Brentano C, Lechat P, Jaillon P, on behalf of CIBIS II investigators. Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II). Eur Heart J2003;24:552-559.
20. Packer M, Coats AJS, Fowler M, Katus H, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schulz M, DeMets DL, for the carvedilol prospective randomized cumulative survival study group. Effect of carvedilol on survival in severe chronic heart failure. N Eng J Med 2001;344:1651-1658.